Larotrectinib | List of Frontiers open access articles

Original Research

Published on 31 Jan 2024

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

in Pharmacology of Anti-Cancer Drugs

Zhiwei Cui
Zhen Zhai
De Xie
Lihui Wang
Feiyan Cheng
Siyu Lou
Fan Zou
Rumeng Pan
Shixue Chang
Haoyan Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1329409

5,496 views
11 citations

Case Report

Published on 29 Sep 2025

Case Report: Novel findings of larotrectinib in children with NTRK-rearranged spindle cell tumor

in Pediatric Oncology

Linnan Wu
Weiji Xie
Juan Wang
Suying Lu
Yizhuo Zhang
Junting Huang

Frontiers in Oncology

doi 10.3389/fonc.2025.1561051

2,378 views
1 citation

Case Report

Published on 07 Nov 2022

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

in Thoracic Oncology

Chiara Lazzari
Lorenza Pecciarini
Claudio Doglioni
Federica Pedica
Ana Maria Samanes Gajate
Alessandra Bulotta
Vanesa Gregorc
Maria Giulia Cangi

Frontiers in Oncology

doi 10.3389/fonc.2022.1038774

4,509 views
8 citations

Mini Review

Published on 07 Dec 2023

Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases

in Pediatric Oncology

Selene Cipri
Francesco Fabozzi
Giada Del Baldo
Giuseppe Maria Milano
Luigi Boccuto
Andrea Carai
Angela Mastronuzzi

Frontiers in Oncology

doi 10.3389/fonc.2023.1235794

3,052 views

Case Report

Published on 27 Jul 2023

Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Dandan Wang
Fanhui Zhang
Wanli Feng
Jiarong Pan
Tianming Yuan

Frontiers in Oncology

doi 10.3389/fonc.2023.1206833

3,380 views
6 citations

Original Research

Published on 14 Jun 2022

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

in Regulatory Science

Jorn Mulder
Odile C. van Stuijvenberg
Paula B. van Hennik
Emile E. Voest
Anna M. G. Pasmooij
Violeta Stoyanova-Beninska
Anthonius de Boer

Frontiers in Medicine

doi 10.3389/fmed.2022.893400

5,096 views
7 citations

Case Report

Published on 09 Oct 2023

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report

in Molecular and Cellular Oncology

Emanuela Palmerini
Giorgio Frega
Marco Gambarotti
Tommaso Frisoni
Marilena Cesari
Alberto Bazzocchi
Marco Miceli
Davide Maria Donati
Stefano Fanti
Cristina Nanni

Frontiers in Oncology

doi 10.3389/fonc.2023.1252359

3,777 views
8 citations

Case Report

Published on 07 Jan 2022

Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy

in Pharmacology of Anti-Cancer Drugs

Federica Recine
Alessandro De Vita
Valentina Fausti
Federica Pieri
Alberto Bongiovanni
Eugenia Franchini
Roberto Casadei
Maria Cristina Falasconi
Devil Oboldi
Federica Matteucci

Frontiers in Oncology

doi 10.3389/fonc.2021.740676

8,279 views
29 citations

Case Report

Published on 20 Nov 2024

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma

in Pharmacology of Anti-Cancer Drugs

Luigia Turco
Rosa Della Monica
Pasqualina Giordano
Mariella Cuomo
Manuele Biazzo
Baptiste Mateu
Raimondo Di Liello
Bruno Daniele
Nicola Normanno
Antonella De Luca

Frontiers in Oncology

doi 10.3389/fonc.2024.1458990

2,666 views
3 citations

Case Report

Published on 23 Feb 2023

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene

in Pediatric Oncology

Catherine Cervi
Zoltán Sápi
Gábor Bedics
Erik Zajta
Lajos Hegyi
Judit Pápay
Katalin Dezső
Edit Varga
Katalin Mudra
Csaba Bödör

Frontiers in Oncology

doi 10.3389/fonc.2023.999810

3,584 views
5 citations

Original Research

Published on 14 Jun 2021

Genomic Landscape of Head and Neck Squamous Cell Carcinoma Across Different Anatomic Sites in Chinese Population

in Cancer Genetics and Oncogenomics

Yunhe Ju
Xingrao Wu
Huizhen Wang
Bin Li
Qing Long
Dadong Zhang
Hao Chen
Nianqing Xiao
Fugen Li
Shiwen Zhang

Frontiers in Genetics

doi 10.3389/fgene.2021.680699

8,982 views
18 citations

Original Research

Published on 17 Jul 2024

The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases

in Cancer Molecular Targets and Therapeutics

Philippe Metellus
Clara Camilla
Emilie Bialecki
Nathalie Beaufils
Christine Vellutini
Eric Pellegrino
Pascale Tomasini
Manmeet S. Ahluwalia
Alireza Mansouri
Isabelle Nanni

Frontiers in Oncology

doi 10.3389/fonc.2024.1382394

4,605 views

Case Report

Published on 06 Aug 2025

NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report

in Respiratory Pharmacology

Jielin Li
Yunyun Shi
Mengge Zheng
Chenkang Yang
Hong Gao
Xiaoling Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1571777

2,803 views

Case Report

Published on 06 Jun 2025

Primary pancreas NTRK-rearranged neoplasm harboring an EVT6::NTRK3 fusion with a sclerosing epithelioid fibrosarcoma morphology: a case report and comprehensive review of the literature

in Cancer Genetics

Xin Wu
Dujuan Li
Fangfang Fu
Lifei Lian

Frontiers in Oncology

doi 10.3389/fonc.2025.1526281

2,925 views

Original Research

Published on 14 Jul 2023

Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed

in Precision Medicine

Adriana Ceci
Rosa Conte
Antonella Didio
Annalisa Landi
Lucia Ruggieri
Viviana Giannuzzi
Fedele Bonifazi

Frontiers in Medicine

doi 10.3389/fmed.2023.1113460

3,501 views
2 citations

Original Research

Published on 01 Jun 2023

Drug delivery system for the extended-release of larotrectinib based on a biocompatible Fe-based metal-organic framework: synthesis, characterization, in vitro release properties and antitumor evaluation

in Nanobiotechnology

Lu Gan
Peng Ji
Jin-xiang Zhang
Hao Chen
Yan-sheng Yao
Zhen-kun Ren

Frontiers in Bioengineering and Biotechnology

doi 10.3389/fbioe.2023.1197484

5,129 views
12 citations

Articles

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Case Report: Novel findings of larotrectinib in children with NTRK-rearranged spindle cell tumor

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases

Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report

Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene

Genomic Landscape of Head and Neck Squamous Cell Carcinoma Across Different Anatomic Sites in Chinese Population

The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases

NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report

Primary pancreas NTRK-rearranged neoplasm harboring an EVT6::NTRK3 fusion with a sclerosing epithelioid fibrosarcoma morphology: a case report and comprehensive review of the literature

Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed

Drug delivery system for the extended-release of larotrectinib based on a biocompatible Fe-based metal-organic framework: synthesis, characterization, in vitro release properties and antitumor evaluation